ProCE Banner Activity

Pembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC

Slideset Download
Conference Coverage
Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals